People with metastatic PDAC have poor outcomes. Despite contemporary chemotherapy regimens with gemcitabine + nab-paclitaxel and FOLFIRINOX, the median overall survival is between 8.5-11 months. A significant proportion of patients fail to receive second line chemotherapy, highlighting the need for a more effective treatment combination in the first line setting.
ASCEND aims to investigate the activity and safety of CEND-1/LSTA1 as an addition to first line gemcitabine and nab- paclitaxel in people with untreated metastatic pancreatic ductal adenocarcinoma (PDAC). The results of this study will inform future comparative phase III randomised controlled trials.
A/Prof Andrew Dean
Wednesday, 15 November
Session 1: Upper GI and HPB Cancer (Advanced) – Progress in trials and management